What is StrideBio?
StrideBio is at the forefront of gene therapy development, dedicated to creating best-in-class therapies for individuals afflicted with life-threatening diseases. The company's mission is to lead the evolution of gene therapy through superior drug development and adherence to high industry standards. StrideBio emphasizes integrity and innovation, striving to translate scientific advancements into effective treatments that enhance and prolong lives. Key to their offerings is the STRIVE Capsid Platform, complemented by comprehensive AAV manufacturing services, positioning them as a significant player in the biotech landscape.
How much funding has StrideBio raised?
StrideBio has raised a total of $97.2M across 2 funding rounds:
Series A
$15.7M
Series B
$81.5M
Series A (2018): $15.7M with participation from Hatteras Venture Partners, Alexandria Venture Investments, Takeda Ventures, and UCB
Series B (2021): $81.5M led by Caas Capital Management, Pontifax, Northpond Ventures, Sarepta Therapeutics, Novo Holdings, UF Innovate Ventures, and Octagon Capital
Key Investors in StrideBio
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm specializing in transformative companies within the biotech, MedTech, and HealthTech sectors. They are known for investing in innovative healthcare solutions and providing strategic support to founders.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc., operating as Alexandria Venture Investments, is a real estate investment trust focused on properties for the life sciences industry, supporting research and development entities.
Takeda Ventures
Takeda Ventures is associated with Takeda Pharmaceutical Company, a global biopharmaceutical leader engaged in the research, development, and marketing of pharmaceutical products across various therapeutic areas.
What's next for StrideBio?
With the recent infusion of major strategic capital, StrideBio is poised to accelerate its research and development initiatives. This significant investment, part of its overall funding of $97.2M, will likely fuel the expansion of its therapeutic pipeline and enhance its AAV manufacturing capabilities. The company's focus on developing superior gene therapies suggests a strategic direction towards scaling operations and potentially advancing its lead candidates through clinical trials. The sustained backing from prominent investors indicates a strong belief in StrideBio's potential to address unmet medical needs and achieve significant growth in the competitive gene therapy market.
See full StrideBio company page
